JP2006517090A - 合成遺伝子 - Google Patents
合成遺伝子 Download PDFInfo
- Publication number
- JP2006517090A JP2006517090A JP2004540296A JP2004540296A JP2006517090A JP 2006517090 A JP2006517090 A JP 2006517090A JP 2004540296 A JP2004540296 A JP 2004540296A JP 2004540296 A JP2004540296 A JP 2004540296A JP 2006517090 A JP2006517090 A JP 2006517090A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- synthon
- site
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700005078 Synthetic Genes Proteins 0.000 title claims abstract description 178
- 239000013598 vector Substances 0.000 claims abstract description 462
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 339
- 238000000034 method Methods 0.000 claims abstract description 263
- 108010030975 Polyketide Synthases Proteins 0.000 claims abstract description 257
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 199
- 229920001184 polypeptide Polymers 0.000 claims abstract description 196
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 196
- 229930001119 polyketide Natural products 0.000 claims abstract description 62
- 108020004414 DNA Proteins 0.000 claims description 162
- 108091034117 Oligonucleotide Proteins 0.000 claims description 144
- 108091008146 restriction endonucleases Proteins 0.000 claims description 137
- 239000012634 fragment Substances 0.000 claims description 101
- 108700026244 Open Reading Frames Proteins 0.000 claims description 96
- 239000003550 marker Substances 0.000 claims description 95
- 108020004705 Codon Proteins 0.000 claims description 89
- 239000002773 nucleotide Substances 0.000 claims description 81
- 125000003729 nucleotide group Chemical group 0.000 claims description 80
- 108091026890 Coding region Proteins 0.000 claims description 74
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 73
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 67
- 238000013461 design Methods 0.000 claims description 63
- 150000001413 amino acids Chemical class 0.000 claims description 58
- 238000003752 polymerase chain reaction Methods 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 43
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 41
- 230000008569 process Effects 0.000 claims description 39
- 150000003881 polyketide derivatives Chemical class 0.000 claims description 37
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 238000003780 insertion Methods 0.000 claims description 35
- 230000037431 insertion Effects 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000008520 organization Effects 0.000 claims description 30
- 230000003321 amplification Effects 0.000 claims description 26
- 210000004899 c-terminal region Anatomy 0.000 claims description 26
- 108700010070 Codon Usage Proteins 0.000 claims description 25
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 25
- 102000012463 Thioesterase domains Human genes 0.000 claims description 21
- 108050002018 Thioesterase domains Proteins 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 21
- 238000011068 loading method Methods 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 18
- 238000007845 assembly PCR Methods 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 230000029087 digestion Effects 0.000 claims description 15
- 238000009940 knitting Methods 0.000 claims description 11
- 239000013599 cloning vector Substances 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 9
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims description 6
- 238000012988 high-throughput synthesis Methods 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 108091093088 Amplicon Proteins 0.000 claims description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 claims description 3
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 33
- -1 polyketide compounds Chemical class 0.000 abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 description 77
- 230000015572 biosynthetic process Effects 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 55
- 229940024606 amino acid Drugs 0.000 description 53
- 238000010367 cloning Methods 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 38
- 239000000047 product Substances 0.000 description 35
- 102000005421 acetyltransferase Human genes 0.000 description 33
- 108020002494 acetyltransferase Proteins 0.000 description 33
- 238000010276 construction Methods 0.000 description 32
- 230000000694 effects Effects 0.000 description 29
- 239000010437 gem Substances 0.000 description 29
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 239000002157 polynucleotide Substances 0.000 description 29
- 239000000523 sample Substances 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 28
- 101710146995 Acyl carrier protein Proteins 0.000 description 24
- 238000012163 sequencing technique Methods 0.000 description 24
- 238000004422 calculation algorithm Methods 0.000 description 23
- 125000000830 polyketide group Chemical group 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 20
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 20
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 20
- 230000007017 scission Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 238000000137 annealing Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 15
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- 238000005457 optimization Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 11
- 108010042407 Endonucleases Proteins 0.000 description 10
- 102000004533 Endonucleases Human genes 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 108010000785 non-ribosomal peptide synthase Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229930013356 epothilone Natural products 0.000 description 7
- 150000003883 epothilone derivatives Chemical class 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 108091008053 gene clusters Proteins 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000037432 silent mutation Effects 0.000 description 6
- 229940035893 uracil Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 5
- 102000005488 Thioesterase Human genes 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000012938 design process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- 150000007970 thio esters Chemical class 0.000 description 5
- 108020002982 thioesterase Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 4
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 4
- 102100024407 Jouberin Human genes 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000013515 script Methods 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 108010082610 Deoxyribonuclease (Pyrimidine Dimer) Proteins 0.000 description 3
- 102000004099 Deoxyribonuclease (Pyrimidine Dimer) Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- JYOAXOMPIXKMKK-YUMQZZPRSA-N Leu-Gln Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCC(N)=O JYOAXOMPIXKMKK-YUMQZZPRSA-N 0.000 description 3
- 101710147059 Nicking endonuclease Proteins 0.000 description 3
- 239000004104 Oleandomycin Substances 0.000 description 3
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 3
- UZQBOFAUUTZOQE-UHFFFAOYSA-N Pikromycin Natural products CC1CC(C)C(=O)C=CC(O)(C)C(CC)OC(=O)C(C)C(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 UZQBOFAUUTZOQE-UHFFFAOYSA-N 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- HUKYPYXOBINMND-UHFFFAOYSA-N methymycin Natural products CC1CC(C)C(=O)C=CC(O)(C)C(CC)OC(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 HUKYPYXOBINMND-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 3
- 235000019367 oleandomycin Nutrition 0.000 description 3
- 229960002351 oleandomycin Drugs 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- UZQBOFAUUTZOQE-VSLWXVDYSA-N pikromycin Chemical compound C[C@H]1C[C@@H](C)C(=O)\C=C\[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)C(=O)[C@H](C)[C@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1 UZQBOFAUUTZOQE-VSLWXVDYSA-N 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 description 2
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101000578253 Xenopus laevis Homeobox protein Nkx-3.2 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- HQZOLNNEQAKEHT-UHFFFAOYSA-N (3R,4S,5R,6S,7S,9R,11R,12S,13R,14R)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione Natural products CCC1OC(=O)C(C)C(O)C(C)C(O)C(C)CC(C)C(=O)C(C)C(O)C1C HQZOLNNEQAKEHT-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 101001030456 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) Adenylate-forming reductase 03009 Proteins 0.000 description 1
- 101001000081 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) Adenylate-forming reductase 06235 Proteins 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 101150002621 EPO gene Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 101001124319 Heterobasidion annosum Adenylate-forming reductase Nps10 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000258241 Mantis Species 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000863434 Myxococcales Species 0.000 description 1
- 241000863422 Myxococcus xanthus Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101150068419 ORF 1 gene Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 101001053399 Paxillus involutus Atromentin synthetase invA1 Proteins 0.000 description 1
- 101001053402 Paxillus involutus Atromentin synthetase invA2 Proteins 0.000 description 1
- 101000599707 Paxillus involutus Atromentin synthetase invA5 Proteins 0.000 description 1
- 101001053396 Paxillus involutus Inactive atromentin synthetase invA3 Proteins 0.000 description 1
- 101000599706 Paxillus involutus Inactive atromentin synthetase invA4 Proteins 0.000 description 1
- 101000599710 Paxillus involutus Inactive atromentin synthetase invA6 Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000187559 Saccharopolyspora erythraea Species 0.000 description 1
- 101100457843 Schizosaccharomyces pombe (strain 972 / ATCC 24843) tit1 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 101001124317 Serpula lacrymans var. lacrymans (strain S7.9) Adenylate-forming reductase Nps11 Proteins 0.000 description 1
- 101000577223 Serpula lacrymans var. lacrymans (strain S7.9) Adenylate-forming reductase Nps9 Proteins 0.000 description 1
- 101001124346 Serpula lacrymans var. lacrymans (strain S7.9) Atromentin synthetase nps3 Proteins 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 241000187758 Streptomyces ambofaciens Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241000187438 Streptomyces fradiae Species 0.000 description 1
- 241000531819 Streptomyces venezuelae Species 0.000 description 1
- 101000691656 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA1, modules 1 and 2 Proteins 0.000 description 1
- 101000691655 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA2, modules 3 and 4 Proteins 0.000 description 1
- 101000691658 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA3, module 5 Proteins 0.000 description 1
- 101001125873 Streptomyces venezuelae Narbonolide/10-deoxymethynolide synthase PikA4, module 6 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101001034059 Suillus grevillei Atromentin synthetase greA Proteins 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 108010064978 Type II Site-Specific Deoxyribonucleases Proteins 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150006252 accA-1 gene Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010064144 endodeoxyribonuclease VII Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000019867 fractionated palm kernal oil Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PNMUAGGSDZXTHX-UHFFFAOYSA-N glycyl-glutamine Chemical compound NCC(=O)NC(C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-UHFFFAOYSA-N 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- OXFYAOOMMKGGAI-JLTOUBQASA-N narbomycin Chemical compound C[C@H]1C[C@@H](C)C(=O)\C=C\[C@@H](C)[C@@H](CC)OC(=O)[C@H](C)C(=O)[C@H](C)[C@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1 OXFYAOOMMKGGAI-JLTOUBQASA-N 0.000 description 1
- OXFYAOOMMKGGAI-UHFFFAOYSA-N narbomycin Natural products CC1CC(C)C(=O)C=CC(C)C(CC)OC(=O)C(C)C(=O)C(C)C1OC1C(O)C(N(C)C)CC(C)O1 OXFYAOOMMKGGAI-UHFFFAOYSA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150036991 pccB gene Proteins 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 101150020468 prpE gene Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 101150056746 sfp gene Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229930185156 spinosyn Natural products 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 108010034149 surfactin synthetase Proteins 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41408502P | 2002-09-26 | 2002-09-26 | |
| PCT/US2003/030940 WO2004029220A2 (en) | 2002-09-26 | 2003-09-26 | Synthetic genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517090A true JP2006517090A (ja) | 2006-07-20 |
| JP2006517090A5 JP2006517090A5 (enExample) | 2006-12-07 |
Family
ID=32043342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004540296A Pending JP2006517090A (ja) | 2002-09-26 | 2003-09-26 | 合成遺伝子 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20040166567A1 (enExample) |
| EP (1) | EP1576140A4 (enExample) |
| JP (1) | JP2006517090A (enExample) |
| AU (1) | AU2003277149A1 (enExample) |
| WO (1) | WO2004029220A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021241593A1 (ja) * | 2020-05-26 | 2021-12-02 | Ｓｐｉｂｅｒ株式会社 | マルチモジュール型生合成酵素遺伝子のコンビナトリアルライブラリーの調製方法 |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
| JP5089984B2 (ja) * | 2003-10-03 | 2012-12-05 | プロメガ コーポレイション | 方向性クローニング用ベクター |
| US8293503B2 (en) * | 2003-10-03 | 2012-10-23 | Promega Corporation | Vectors for directional cloning |
| EP1733055A4 (en) * | 2004-02-27 | 2009-03-11 | Harvard College | polynucleotide |
| US20050227316A1 (en) * | 2004-04-07 | 2005-10-13 | Kosan Biosciences, Inc. | Synthetic genes |
| US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
| AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
| WO2006069099A2 (en) * | 2004-12-21 | 2006-06-29 | Genecopoeia, Inc. | Method and compositions for rapidly modifying clones |
| JP2008526259A (ja) * | 2005-01-13 | 2008-07-24 | コドン デバイシズ インコーポレイテッド | 蛋白質デザインのための組成物及び方法 |
| WO2006081177A2 (en) * | 2005-01-24 | 2006-08-03 | Decode Biostructures, Inc. | Gene synthesis software |
| ATE545701T1 (de) * | 2005-05-17 | 2012-03-15 | Ozgene Pty Ltd | Sequentielles klonierungssystem |
| US20060281113A1 (en) * | 2005-05-18 | 2006-12-14 | George Church | Accessible polynucleotide libraries and methods of use thereof |
| US20070004041A1 (en) * | 2005-06-30 | 2007-01-04 | Codon Devices, Inc. | Heirarchical assembly methods for genome engineering |
| US20070184487A1 (en) * | 2005-07-12 | 2007-08-09 | Baynes Brian M | Compositions and methods for design of non-immunogenic proteins |
| WO2007009082A1 (en) * | 2005-07-12 | 2007-01-18 | Codon Devices, Inc. | Compositions and methods for biocatalytic engineering |
| US20090087840A1 (en) * | 2006-05-19 | 2009-04-02 | Codon Devices, Inc. | Combined extension and ligation for nucleic acid assembly |
| US8053191B2 (en) | 2006-08-31 | 2011-11-08 | Westend Asset Clearinghouse Company, Llc | Iterative nucleic acid assembly using activation of vector-encoded traits |
| US20100291633A1 (en) * | 2007-09-03 | 2010-11-18 | Thorsten Selmer | Method of cloning at least one nucleic acid molecule of interest using type iis restriction endonucleases, and corresponding cloning vectors, kits and system using type iis restriction endonucleases |
| DK2294407T3 (en) * | 2008-06-06 | 2017-05-15 | Dna Twopointo Inc | SYSTEMS AND PROCEDURES FOR DETERMINING PROPERTIES THAT AFFECT THE EXPRESSION PROPERTY VALUE OF POLYNUCLEOTIDES IN AN EXPRESSION SYSTEM |
| US8551545B2 (en) * | 2008-11-18 | 2013-10-08 | Kraft Foods Group Brands Llc | Food package for segregating ingredients of a multi-component food product |
| WO2011056872A2 (en) | 2009-11-03 | 2011-05-12 | Gen9, Inc. | Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly |
| WO2011066185A1 (en) | 2009-11-25 | 2011-06-03 | Gen9, Inc. | Microfluidic devices and methods for gene synthesis |
| WO2011085075A2 (en) | 2010-01-07 | 2011-07-14 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
| EP2395087A1 (en) * | 2010-06-11 | 2011-12-14 | Icon Genetics GmbH | System and method of modular cloning |
| CA2817697C (en) | 2010-11-12 | 2021-11-16 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
| WO2012064975A1 (en) | 2010-11-12 | 2012-05-18 | Gen9, Inc. | Protein arrays and methods of using and making the same |
| JP2014526899A (ja) | 2011-08-26 | 2014-10-09 | ジェン９・インコーポレイテッド | 核酸の高忠実度アセンブリのための組成物および方法 |
| US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
| CA2871505C (en) | 2012-04-24 | 2021-10-12 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
| WO2014004393A1 (en) | 2012-06-25 | 2014-01-03 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
| US10331146B2 (en) | 2013-03-15 | 2019-06-25 | Lantheus Medical Imaging, Inc. | Control system for radiopharmaceuticals |
| KR102160389B1 (ko) | 2013-08-05 | 2020-09-28 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
| CA2975855C (en) | 2015-02-04 | 2025-09-23 | Twist Bioscience Corporation | SYNTHETIC GENE COMPOSITIONS AND ASSEMBLY METHODS |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| WO2017053450A1 (en) | 2015-09-22 | 2017-03-30 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| EP3384077A4 (en) | 2015-12-01 | 2019-05-08 | Twist Bioscience Corporation | FUNCTIONALIZED SURFACES AND MANUFACTURE THEREOF |
| WO2018038772A1 (en) | 2016-08-22 | 2018-03-01 | Twist Bioscience Corporation | De novo synthesized nucleic acid libraries |
| EP4664304A3 (en) | 2016-09-21 | 2026-01-21 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| GB2573069A (en) | 2016-12-16 | 2019-10-23 | Twist Bioscience Corp | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| CA3056388A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| EP3688167A4 (en) * | 2017-09-29 | 2021-07-14 | Victoria Link Limited | SYSTEM FOR MODULAR DNA ARRANGEMENT |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| IL312616B2 (en) | 2018-01-04 | 2025-08-01 | Twist Bioscience Corp | Dna-based digital information storage |
| EP3814497A4 (en) | 2018-05-18 | 2022-03-02 | Twist Bioscience Corporation | POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS |
| CA3131689A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| KR20210144698A (ko) | 2019-02-26 | 2021-11-30 | 트위스트 바이오사이언스 코포레이션 | 항체 최적화를 위한 변이 핵산 라이브러리 |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| AU2020400030B2 (en) | 2019-12-09 | 2026-05-21 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013663A1 (en) * | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| JPH07313166A (ja) * | 1993-01-25 | 1995-12-05 | American Cyanamid Co | 昆虫毒素ＡａＩＴに関するコドン最適化ＤＮＡ配列 |
| JPH11511334A (ja) * | 1995-09-22 | 1999-10-05 | ザ ジェネラル ホスピタル コーポレーション | 蛋白質の高レベル発現 |
| WO2000063361A2 (en) * | 1999-04-16 | 2000-10-26 | Kosan Biosciences, Inc. | A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| WO2001092991A2 (en) * | 2000-05-30 | 2001-12-06 | Kosan Biosciences, Inc. | Design of polyketide synthase genes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824513A (en) * | 1991-01-17 | 1998-10-20 | Abbott Laboratories | Recombinant DNA method for producing erythromycin analogs |
| US6066721A (en) * | 1995-07-06 | 2000-05-23 | Stanford University | Method to produce novel polyketides |
| US5552278A (en) * | 1994-04-04 | 1996-09-03 | Spectragen, Inc. | DNA sequencing by stepwise ligation and cleavage |
| US6358712B1 (en) * | 1999-01-05 | 2002-03-19 | Trustee Of Boston University | Ordered gene assembly |
| US7001748B2 (en) * | 1999-02-09 | 2006-02-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of making polyketides using hybrid polyketide synthases |
| US20020025561A1 (en) * | 2000-04-17 | 2002-02-28 | Hodgson Clague Pitman | Vectors for gene-self-assembly |
| EP1227157A1 (en) * | 2001-01-19 | 2002-07-31 | Galapagos Genomics B.V. | Swap/counter selection: a rapid cloning method |
| US20030087254A1 (en) * | 2001-04-05 | 2003-05-08 | Simon Delagrave | Methods for the preparation of polynucleotide libraries and identification of library members having desired characteristics |
-
2003
- 2003-09-26 US US10/672,396 patent/US20040166567A1/en not_active Abandoned
- 2003-09-26 EP EP03798802A patent/EP1576140A4/en not_active Withdrawn
- 2003-09-26 AU AU2003277149A patent/AU2003277149A1/en not_active Abandoned
- 2003-09-26 WO PCT/US2003/030940 patent/WO2004029220A2/en not_active Ceased
- 2003-09-26 JP JP2004540296A patent/JP2006517090A/ja active Pending
-
2007
- 2007-08-20 US US11/894,641 patent/US20080274510A1/en not_active Abandoned
- 2007-08-20 US US11/894,753 patent/US20080261300A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013663A1 (en) * | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| JPH07313166A (ja) * | 1993-01-25 | 1995-12-05 | American Cyanamid Co | 昆虫毒素ＡａＩＴに関するコドン最適化ＤＮＡ配列 |
| JPH11511334A (ja) * | 1995-09-22 | 1999-10-05 | ザ ジェネラル ホスピタル コーポレーション | 蛋白質の高レベル発現 |
| WO2000063361A2 (en) * | 1999-04-16 | 2000-10-26 | Kosan Biosciences, Inc. | A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| WO2001092991A2 (en) * | 2000-05-30 | 2001-12-06 | Kosan Biosciences, Inc. | Design of polyketide synthase genes |
Non-Patent Citations (7)
| Title |
|---|
| JPN6009057907, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓ．，Ｖｏｌ．１６，Ｎｏ．２２（１９８８）ｐ．１０４５３−１０４６７ * |
| JPN6009057908, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓ．，Ｖｏｌ．１６，Ｎｏ．５（１９８８）ｐ．１６９３−１７０２ * |
| JPN6009057909, Ｂｉｏｔｅｃｈｎｉｑｕｅｓ，Ｖｏｌ．１６，Ｎｏ．６（１９９４）ｐ．１１１６−１１２３ * |
| JPN6009057910, Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓ．，Ｖｏｌ．３０，Ｎｏ．１０（２００２．Ｍａｙ）ｐ．ｅ４３ * |
| JPN6009057911, Ｓｃｉｅｎｃｅ，Ｖｏｌ．２８２，Ｎｏ．５３８６（１９９８）ｐ．６３−６８ * |
| JPN6009057912, Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ．，Ｖｏｌ．９６，Ｎｏ．５（１９９９）ｐ．１８４６−１８５１ * |
| JPN6009057913, Ｐｒｏｔｅｉｎ Ｓｃｉ．，Ｖｏｌ．６，Ｎｏ．８（１９９７）ｐ．１６５３−１６６０ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021241593A1 (ja) * | 2020-05-26 | 2021-12-02 | Ｓｐｉｂｅｒ株式会社 | マルチモジュール型生合成酵素遺伝子のコンビナトリアルライブラリーの調製方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1576140A2 (en) | 2005-09-21 |
| WO2004029220A2 (en) | 2004-04-08 |
| WO2004029220A3 (en) | 2006-04-06 |
| AU2003277149A1 (en) | 2004-04-19 |
| US20080274510A1 (en) | 2008-11-06 |
| US20080261300A1 (en) | 2008-10-23 |
| EP1576140A4 (en) | 2007-08-08 |
| US20040166567A1 (en) | 2004-08-26 |
| AU2003277149A8 (en) | 2004-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517090A5 (enExample) | ||
| US20040166567A1 (en) | Synthetic genes | |
| Li et al. | Establishing a high yielding streptomyces‐based cell‐free protein synthesis system | |
| Orelle et al. | Protein synthesis by ribosomes with tethered subunits | |
| JP2007533308A (ja) | 合成遺伝子 | |
| Esposito et al. | Gateway cloning for protein expression | |
| US20230183678A1 (en) | In-cell continuous target-gene evolution, screening and selection | |
| US20190264184A1 (en) | Compositions and methods for the production of compounds | |
| CN111315883A (zh) | 用于全长t细胞受体可读框的快速装配和多样化的两组分载体文库系统 | |
| Gao et al. | Challenges of functional expression of complex polyketide biosynthetic gene clusters | |
| US20210123065A1 (en) | Recombination systems for high-throughput chromosomal engineering of bacteria | |
| CN107746826A (zh) | 一种通过共表达林可链霉菌中metK1和metK2基因提高林可霉素产量的方法 | |
| Herynek et al. | Increasing recombinant protein production in E. coli via FACS‐based selection of N‐terminal coding DNA libraries | |
| JP2025526940A (ja) | 非リボソームペプチドを工学的に生成する方法および手段 | |
| Blažič et al. | Annotation of the modular polyketide synthase and nonribosomal peptide synthetase gene clusters in the genome of Streptomyces tsukubaensis NRRL18488 | |
| Segall-Shapiro et al. | Mesophilic and hyperthermophilic adenylate kinases differ in their tolerance to random fragmentation | |
| Takada et al. | Differential regulation of rRNA and tRNA transcription from the rRNA-tRNA composite operon in Escherichia coli | |
| Płachetka et al. | Streptomycete origin of chromosomal replication with two putative unwinding elements | |
| US20230295612A1 (en) | Method for screening for bioactive natural products | |
| Chen et al. | AP profiling resolves co-translational folding pathway and chaperone interactions in vivo | |
| CN101538579B (zh) | 一种构建和生产限制性内切酶Ecop15I的方法 | |
| US20020038000A1 (en) | Systematic polypeptide evolution by reverse translation | |
| EP4424820A1 (en) | Designed synzip protein domains for generating artificial nonribosomal peptide synthetases and hybrids thereof | |
| Horswill et al. | Identifying small‐molecule modulators of protein‐protein interactions | |
| Eleftheraki et al. | An RNA structural switch controlling bacterial toxin translation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060925 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060925 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20061018 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20081217 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |